RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, ...

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared ...

In patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI), stenting demonstrated improved ...

No-touch’ vein harvesting significantly reduces the risk of graft failure up to three years after coronary artery bypass ...

The no-touch vein harvesting technique significantly lowers the risk of graft failure for up to three years after coronary ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

No-touch' vein harvesting significantly reduces the risk of graft failure up to three years after coronary artery bypass surgery compared with ...

No-touch’ vein harvesting significantly reduces the risk of graft failure up to three years after coronary artery bypass surgery compared with conventionally harvested vein grafts, finds a study from ...